Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Pegenzileukin in Unresectable Pleural Malignant Mesothelioma: NCT04914897 Clinical Landscape Report 2026
28 September 2026
NCT04914897 clinical landscape for Unresectable Pleural Malignant Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Viltolarsen in Muscular Dystrophy, Duchenne: NCT04956289 Clinical Landscape Report 2026
28 September 2026
NCT04956289 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dostarlimab-gxly in Malignant Pleural Mesothelioma: NCT04940637 Clinical Landscape Report 2026
28 September 2026
NCT04940637 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Atezolizumab in Malignant Pleural Mesothelioma: NCT04996017 Clinical Landscape Report 2026
28 September 2026
NCT04996017 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TT-4 in Malignant Pleural Mesothelioma: NCT04969315 Clinical Landscape Report 2026
28 September 2026
NCT04969315 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mitomycin in Malignant Mesothelioma of Peritoneum: NCT05001880 Clinical Landscape Report 2026
28 September 2026
NCT05001880 clinical landscape for Malignant Mesothelioma of Peritoneum: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Ipilimumab in Malignant Mesothelioma of Peritoneum: NCT05041062 Clinical Landscape Report 2026
28 September 2026
NCT05041062 clinical landscape for Malignant Mesothelioma of Peritoneum: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Bintrafusp alfa in Malignant Pleural Mesothelioma: NCT05005429 Clinical Landscape Report 2026
28 September 2026
NCT05005429 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
KZR-261 in Uveal Melanoma: NCT05047536 Clinical Landscape Report 2026
28 September 2026
NCT05047536 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Metoprolol Succinate in Cardiomyopathies: NCT05066633 Clinical Landscape Report 2026
28 September 2026
NCT05066633 clinical landscape for Cardiomyopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Unresectable Pleural Malignant Mesothelioma: NCT05071014 Clinical Landscape Report 2026
28 September 2026
NCT05071014 clinical landscape for Unresectable Pleural Malignant Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Tocilizumab in Pancreatic adenocarcinoma: NCT05070247 Clinical Landscape Report 2026
28 September 2026
NCT05070247 clinical landscape for Pancreatic adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.